Superstring Capital Management’s Cidara Therapeutics CDTX Stock Holding History

Superstring Capital Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-85,098	Closed	-$18.8M	–	40
2025 Q4	$18.8M	Buy	85,098 +16,635	+24%	+$2.69M	10.06%	1
2025 Q3	$6.56M	Buy	+68,463	New	+$4.37M	6.46%	2

Superstring Capital Management's CDTX Position: Q1 2026 in Review

Superstring Capital Management sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 85,098 shares — an estimated $18.8M sold.

Superstring Capital Management first reported a position in CDTX in Q3 2025 and held it in 2 quarters. The position peaked at $18.8M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Superstring Capital Management reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Superstring Capital Management sold 85,098 Cidara Therapeutics shares in Q1 2026, an estimated $18.8M.
Superstring Capital Management first reported a position in Cidara Therapeutics in Q3 2025 and held it in 2 quarters.
Superstring Capital Management's Cidara Therapeutics position peaked at $18.8M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Superstring Capital Management's 13F filing for Q1 2026, filed 14 May 2026.